William Blair Analysts Reduce Earnings Estimates for Shire PLC (SHPG)
Shire PLC (NASDAQ:SHPG) – Research analysts at William Blair decreased their FY2019 EPS estimates for Shire PLC in a research report issued on Monday. William Blair analyst T. Lugo now expects that the biopharmaceutical company will earn $18.17 per share for the year, down from their previous estimate of $18.27. William Blair also issued estimates for Shire PLC’s FY2020 earnings at $19.62 EPS.
SHPG has been the topic of several other reports. BidaskClub lowered shares of Shire PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Barclays PLC lowered shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Evercore ISI assumed coverage on shares of Shire PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 target price on the stock. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $213.00 target price on shares of Shire PLC in a report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $219.25.
Shire PLC (NASDAQ SHPG) traded down 1.74% during trading on Wednesday, reaching $145.25. 1,078,686 shares of the company’s stock traded hands. Shire PLC has a 12 month low of $139.36 and a 12 month high of $192.64. The company has a market cap of $43.26 billion, a P/E ratio of 64.99 and a beta of 1.63. The firm’s 50 day moving average is $154.09 and its 200 day moving average is $164.39.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%.
The company also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be given a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Maverick Capital Ltd. grew its position in shares of Shire PLC by 19.9% in the 2nd quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock valued at $320,969,000 after acquiring an additional 322,610 shares during the period. Glenview Capital Management LLC grew its position in shares of Shire PLC by 69.7% in the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after acquiring an additional 707,500 shares during the period. Vanguard Group Inc. grew its position in shares of Shire PLC by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after acquiring an additional 13,665 shares during the period. Ameriprise Financial Inc. grew its position in shares of Shire PLC by 14.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock valued at $249,577,000 after acquiring an additional 194,059 shares during the period. Finally, BlackRock Inc. grew its position in shares of Shire PLC by 4,217.7% in the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after acquiring an additional 1,400,275 shares during the period. 19.24% of the stock is owned by institutional investors.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.